Powered By
FcRn blockers have become important treatment options for some people with generalized myasthenia gravis. Rather than broadly suppressing the immune system, these medications lower levels of specific proteins involved in myasthenia gravis attacks.
Some FcRn blockers are given in treatment cycles, with periods of receiving treatment followed by breaks. Others are given continuously on a regular schedule. This difference can affect everything from how often you receive treatment to how your doctor monitors your response.
Here’s what FcRn blockers are, how they work, what cyclic dosing means, and what to know about effectiveness and side effects.
Sign up to view the results!
Continue with Facebook
Continue with Email
“FcRn” stands for “neonatal Fc receptor.” This protein protects immunoglobulin G (IgG) antibodies from being broken down.
In myasthenia gravis, some IgG antibodies mistakenly attack proteins involved in communication between nerves and muscles. These are known as autoantibodies. FcRn blockers interfere with antibody recycling, allowing more IgG antibodies, including harmful myasthenia gravis autoantibodies, to be broken down naturally.
As levels of autoantibodies decrease, they may interfere less with communication between nerves and muscles. That can lead to improvements in symptoms and everyday activities for some people with generalized myasthenia gravis.
The U.S. Food and Drug Administration (FDA) has approved several FcRn-targeting medications for generalized myasthenia gravis:
Other drugs targeting FcRn continue to be studied, so this area of treatment for myasthenia gravis is still evolving.
There isn’t one treatment plan that works for everyone with myasthenia gravis. Your neurologist may consider an FcRn blocker based on which autoantibodies you test positive for, which symptoms you have, and how they affect your daily life. They’ll also consider your previous treatments, other health conditions, and treatment goals.
An FcRn blocker may be considered when myasthenia gravis symptoms remain hard to manage despite other treatments. It might also be an option when side effects make another medication difficult to continue. FcRn blockers can work relatively quickly compared with some traditional immune-suppressing drugs, so the need for faster symptom relief may also factor into treatment decisions.
Antibody status also matters because FDA-approved uses differ among these medications. Ask your neurologist which FcRn treatment might be best for you.
If you’re researching an FcRn blocker for myasthenia gravis, you’ll probably see the term “cyclic dosing.” Cyclic treatment involves several doses over a set period, followed by a break. Another cycle may be given based on the medication’s dosing instructions and how you respond to treatment.
Why the break? FcRn blockers temporarily lower IgG antibodies rather than permanently eliminating the antibodies. After treatment stops, IgG levels gradually rise again. For some people with myasthenia gravis, symptoms may eventually return or worsen.
Efgartigimod alfa-fcab is generally given once weekly by IV for four weeks. Each infusion takes about one hour. Additional cycles are based on how you respond to treatment.
Efgartigimod alfa and hyaluronidase-qvfc is a formulation given as an injection under the skin. It also uses cyclic dosing, with one injection each week for four weeks.
Rozanolixizumab-noli is given as a subcutaneous infusion once weekly for six weeks, making six doses in a treatment cycle. Each dose is administered over about 15 minutes using an infusion pump. Additional cycles depend on how you respond.
Nipocalimab-aahu follows a regular dosing schedule rather than an on-and-off cycle. After an initial loading dose, it’s given by IV infusion every two weeks.
When planning treatment, your neurologist may consider how much your symptoms improve, how long improvement lasts, and whether symptoms return.
Clinical trials have shown that FcRn blockers can improve everyday functioning in some people with generalized myasthenia gravis.
Researchers commonly use the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale to measure treatment benefits. The scale measures difficulties with activities such as talking, chewing, swallowing, breathing, getting out of a chair, and seeing clearly.
In the phase three ADAPT trial, 68 percent of AChR-antibody-positive participants receiving efgartigimod had a meaningful improvement in their MG-ADL scores during the first treatment cycle, compared with 30 percent receiving a placebo (an inactive treatment). The ADAPT SERON trial also reported positive results in people with generalized myasthenia gravis who do not have AChR antibodies.
Phase 3 trials of rozanolixizumab-noli and nipocalimab-aahu also found greater improvement in MG-ADL scores with treatment than with a placebo.
Individual responses vary, however. One person may experience a noticeable improvement relatively quickly, while another may have less improvement or no meaningful benefit.
These drugs also haven’t been compared directly in large head-to-head clinical trials. That means results from separate trials can’t show whether one FcRn blocker works better than another.
There’s no set number of weeks or treatment cycles that determines whether an FcRn blocker is working well enough.
Your neurologist will look at whether your symptoms and ability to handle everyday activities have meaningfully improved. With cyclic drugs, they may also consider how long the benefits last between cycles and whether symptoms consistently return before another cycle.
That makes tracking your symptoms useful. Keeping notes about swallowing, speech, vision, arm or leg strength, fatigue, and daily activities can help you and your doctor recognize patterns between treatments.
If you aren’t getting enough benefit, your neurologist can reassess your treatment. Switching to another targeted therapy may be an option, although research on the best ways to switch between newer medications for myasthenia gravis is still developing.
Never change your medication or dosing schedule without talking to your doctor.
Because FcRn blockers lower IgG, they can affect part of your immune system’s ability to fight infections. Side effects vary by medication but may include:
More serious risks include infections and severe allergic or hypersensitivity reactions. Aseptic meningitis (a condition that causes inflammation of the tissues surrounding the brain and spinal cord) has also been reported with rozanolixizumab-noli.
Tell your healthcare team if you develop signs of an infection, such as fever or chills. Treatment may need to be delayed until an active infection has cleared.
Ask your doctor about vaccines before starting an FcRn blocker, too. The timing and type of vaccination may matter, especially for live vaccines.
Seek emergency medical care if you have severe difficulty breathing or swallowing, which could signal a myasthenic crisis.
Newer targeted medications have expanded treatment options for people with myasthenia gravis. You may now have choices that weren’t available a few years ago.
Tell your neurologist what matters most to you. That may be better day-to-day symptom control, fewer flare-ups, reduced corticosteroid use, or a treatment schedule that better fits your life.
If an FcRn blocker isn’t helping enough, ask your doctor what a good response should look like and when to reassess your treatment. Another FcRn blocker that targets a different part of the immune system may be worth discussing.
Get updates directly to your inbox.
Continue with Facebook
Continue with Email
Continue with Facebook
Continue with Email
Become a member to get even more
Join
Your Privacy Choices
This is a member-feature!
Sign up for free to view article comments.
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.